Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01207635 · ClinicalTrials.gov registry record
Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 42
- Enrollment target
NCT01207635: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT01207635 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01207635 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients. Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Breast duct fluid provide biomarkers to aid in risk assessment of developing breast cancer.
Primary Outcome
Biomarker modulation study on effects of Armimidex in ductal lavage fluid from evaluable epithelial cells specimen.
Interventions
- PROCEDURE Ductal Lavage Fluid Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2002-11 |
| Est. Completion | 2006-01 |
What the finished NCT01207635 record still lists
NCT01207635 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Ductal Lavage Fluid Collection is the first listed.
NCT01207635 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01207635 about?
NCT01207635 is a clinical study titled "Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer". The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients. Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Breast duct fluid provide biomarkers to aid in risk assess...
What is the current status of trial NCT01207635?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2002-11. Estimated completion is 2006-01.
What interventions are being tested in trial NCT01207635?
The interventions under investigation include: Ductal Lavage Fluid Collection (PROCEDURE).
Who is sponsoring clinical trial NCT01207635?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia